The LAISOLID project, developed by Laboratorios Farmacéuticos ROVI, has been granted €36.3 million in funding by the Centre for Technological Development and Innovation (CDTI), within the framework of the European IPCEI Med4Cure program. This aid is integrated into the initiatives of the European Union’s Recovery, Transformation and Resilience Plan aimed at strengthening research in the field of health.
The project aims to develop aseptic filling technologies applied to complex polymeric matrices that can incorporate biological materials and active ingredients. These formulations are designed to allow controlled drug release over long periods, with potential applications in advanced therapies and long-term treatments.
